Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

09/13/2021 | 06:08am EDT

Item 7.01 Regulation FD Disclosure.

Matinas BioPharma Holdings, Inc. (the "Company") issued a press release announcing positive efficacy and safety data from the first two cohorts of patients in the ongoing Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial ("EnACT") of MAT2203 (oral amphotericin B) for the treatment of cryptococcal meningitis. A copy of the press release is furnished as Exhibit 99. 1 hereto and incorporated herein by reference.

The Company created a presentation which includes the data from EnACT trial (the "Presentation") which it intends to use during a planned conference call on September 13, 2021 and then at various conferences and investor meetings. The Presentation is attached hereto as Exhibit 99.2.

The Company updated its corporate presentation (the "Corporate Presentation") which it intends to use at various conferences and investor meetings. The Corporate Presentation is attached hereto as Exhibit 99.3.

The information in this Item 7.01 and Exhibits 99.1, 99.2 and 99.3 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 8.01. Other Events.



On September 13, 2021, the Company announced positive efficacy and safety data from the first two cohorts of patients in the ongoing Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) of MAT2203 (oral amphotericin B) for the treatment of cryptococcal meningitis, which is being sponsored by the National Institute of Allergy and Infectious Diseases ("NIAID").

The EnACT independent Data and Safety Monitoring Board ("DSMB") recently completed a pre-specified review of available safety and efficacy data from Cohort 2 (stepdown to MAT2203 after two days of IV amphotericin) and unanimously recommended progression to the second half of the study. Enrollment in Cohort 3 of EnACT (the safety lead-in for Cohort 4, which will be an all-oral MAT2203 treatment regimen) has commenced and is expected to complete by the end of 2021.

Topline Results from Cohort 2 of EnACT

Key topline results from Cohort 2 of EnACT include eradication of the fungal infection, survival, and safety, including longer term use of MAT2203 beyond the 2-week induction period.

Potent Early Fungicidal Activity (EFA), Cerebrospinal Fluid (CSF) Sterilization, with No Evidence of Breakthrough Infections During Treatment with MAT2203

? The primary endpoint in EnACT is EFA, a measurement of cerebrospinal fluid

fungal clearance. EFA is a well-validated quantitative measure of the efficacy

of antifungal agents and is a key surrogate marker for survival. EFAs of less

than 0.20 log10 Cryptococcus colony forming units (CFUs) per mL CSF per day

are associated with significantly higher mortality and worse clinical

outcomes1. EFA measured above this threshold is clinically meaningful and

represents robust fungal clearance. In the second cohort of EnACT, the mean

EFA achieved with patients treated with MAT2203 was 0.38 log10 CFU/mL/day,

with 95% confidence intervals (0.30 to 0.46) significantly higher than the

prespecified primary endpoint threshold of >0.20.

1 *Clin Infect Dis. 2020;71(5):e45-49




-2-







  ? All patients treated with MAT2203 who completed the induction phase achieved
    sterile CSF cultures during treatment (either during induction or early
    consolidation phases).

  ? There was no evidence of breakthrough or relapsed cryptococcal infections
    observed in any of the patients during treatment with MAT2203 through 10
    weeks.




Survival



  ? In Cohort 2, overall survival was 95% in 40 patients randomized to receiving
    MAT2203.




Safety



  ? In both Cohorts 1 and 2, MAT2203 showed no evidence of renal toxicity or
    electrolyte abnormalities attributable to MAT2203, no major safety signals,
    and no use-limiting tolerability issues, even with longer-term treatment with
    MAT2203 extended beyond induction into the consolidation phase, from week 2 to
    week 6.



The Company is preparing to engage with the U.S. Food and Drug Administration ("FDA") to review these data as supportive of a potential early approval of MAT2203 as step-down therapy. These data may also set the stage for potential longer-term treatment options, including prophylaxis, for patients dealing with, or at risk for, deadly invasive fungal infections without the toxicities usually associated with IV amphotericin.

The EnAct trial demonstrated that two days of intravenous amphotericin B followed by rapid transition to oral LNC amphotericin B therapy was well tolerated, resulted in excellent CSF clearance of the Cryptococcus yeast, and had a 95% survival to date.




Forward- Looking Statements



This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the results of the EnECT study, the LNC platform delivery technology, the Company's strategic focus and the future development of its product candidates, including MAT2203, MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company's ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements.

Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; the Company's ability to successfully complete research and further development and commercialization of its product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The Company's product candidates are all in a development stage and are not available for sale or use.

Item 9.01 Financial Statements and Exhibits.




Exhibit No.   Description

99.1            Press Release, dated September 13, 2021.
99.2            Slide Presentation, dated September 13, 2021.
99.3            Corporate Presentation, dated September 13, 2021.
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)




-3-

© Edgar Online, source Glimpses

All news about MATINAS BIOPHARMA HOLDINGS, INC.
10/21MATINAS BIOPHARMA : Doses First Patient in Phase 1 Study of Antibiotic Drug Candidate
MT
10/21Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycos..
GL
10/21MATINAS BIOPHARMA : Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycosi..
GL
09/20MATINAS BIOPHARMA : Announces Accomplished Biotechnology Executive and Drug Developer Kath..
PU
09/20MATINAS BIOPHARMA HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation F..
AQ
09/20MATINAS BIOPHARMA : Announces Accomplished Biotechnology Executive and Drug Developer Kath..
AQ
09/17Matinas Biopharma Holdings, Inc. Announces Resignation of Patrick Le Pore as Director
CI
09/14Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Inves..
GL
09/13MATINAS BIOPHARMA : Says MAT2203 Exceeds Primary Endpoint Threshold of Fungal Clearance in..
MT
09/13MATINAS BIOPHARMA : Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Am..
PU
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 1,88 M - -
Net income 2021 -18,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -11,7x
Yield 2021 -
Capitalization 253 M 253 M -
Capi. / Sales 2021 135x
Capi. / Sales 2022 16,1x
Nbr of Employees 20
Free-Float 96,0%
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,17 $
Average target price 2,75 $
Spread / Average Target 135%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-13.97%253
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-39.42%25 233